Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 4/20 | 0.34 |
| ▸ | RET | P07949 | 7/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL462819 | 0.89 | NTRK1 (0.34) | NTRK1RETNR1H2NR1H3DPP4 | |
| SCHEMBL470523 | 0.84 | NTRK1 (0.35) | NTRK1RETNR1H2GPR119 | |
| SCHEMBL12064744 | 0.83 | NTRK1 (0.34) | NTRK1RETNR1H2GPR119 | |
| SCHEMBL470608 | 0.82 | NTRK1 (0.37) | NTRK1RETNR1H2GPR119MAP3K5 | |
| SCHEMBL12064739 | 0.82 | NTRK1 (0.35) | NTRK1RETNR1H2GPR119MAP3K5 | |
| SCHEMBL12064745 | 0.82 | NTRK1 (0.34) | NTRK1RETNR1H2GPR119 | |
| SCHEMBL460032 | 0.82 | NTRK1 (0.38) | NTRK1RET | |
| SCHEMBL470601 | 0.82 | NTRK1 (0.38) | NTRK1RETNR1H2 | |
| SCHEMBL470486 | 0.81 | NTRK1 (0.36) | NTRK1RETNR1H2GPR119 | |
| SCHEMBL461775 | 0.81 | OPRK1 (0.31) | RETNR1H2NR1H3MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011147951-A1 | CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS | PROSIDION LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |